Blockchain Registration Transaction Record

Quantum BioPharma Targets MS with Novel Myelin-Repair Drug

Quantum BioPharma (NASDAQ: QNTM) is featured in a BioMedWire editorial on MS, highlighting its Lucid-MS drug candidate targeting myelin repair. Learn about the Phase 2-ready therapy and the company's broader portfolio.

This news matters because multiple sclerosis affects nearly 3 million people globally, and current treatments only slow progression. Quantum BioPharma’s Lucid-MS represents a potential paradigm shift—aiming to repair myelin damage rather than just manage symptoms. If successful in Phase 2 trials, it could offer patients a therapy that restores lost function, fundamentally changing the MS treatment landscape. For investors, it highlights a promising biotech with a novel approach and a diversified pipeline.